236 related articles for article (PubMed ID: 23210904)
1. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
Kehler J
Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
[TBL] [Abstract][Full Text] [Related]
2. Patented PDE10A inhibitors: novel compounds since 2007.
Kehler J; Kilburn JP
Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
[TBL] [Abstract][Full Text] [Related]
3. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
[TBL] [Abstract][Full Text] [Related]
4. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
6. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
Zagórska A
Expert Opin Ther Pat; 2020 Feb; 30(2):147-157. PubMed ID: 31874060
[No Abstract] [Full Text] [Related]
10. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
11. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
13. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker.
Dedeurwaerdere S; Wintmolders C; Vanhoof G; Langlois X
J Pharmacol Exp Ther; 2011 Oct; 339(1):210-7. PubMed ID: 21742809
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia.
Walling DP; Banerjee A; Dawra V; Boyer S; Schmidt CJ; DeMartinis N
J Clin Psychopharmacol; 2019; 39(6):575-582. PubMed ID: 31688451
[TBL] [Abstract][Full Text] [Related]
15. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
Vardigan JD; Lange HS; Tye SJ; Fox SV; Smith SM; Uslaner JM
Psychopharmacology (Berl); 2016 Jul; 233(13):2441-50. PubMed ID: 27117142
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
19. Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.
Masilamoni GJ; Uthayathas S; Koenig G; Leventhal L; Papa SM
Neuropharmacology; 2016 Nov; 110(Pt A):449-457. PubMed ID: 27539962
[TBL] [Abstract][Full Text] [Related]
20. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
